Get the Stockscreener App
0.8006
23.02%
-0.2394
Citius Pharmaceuticals Inc stock is traded at $0.8006, with a volume of 18.73M.
It is down -23.02% in the last 24 hours and down -29.77% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$1.04
Open:
$1.18
24h Volume:
18.73M
Relative Volume:
17.31
Market Cap:
$14.79M
Revenue:
-
Net Income/Loss:
$-39.14M
P/E Ratio:
-0.1341
EPS:
-5.97
Net Cash Flow:
$-28.20M
1W Performance:
-23.02%
1M Performance:
-29.77%
6M Performance:
-37.94%
1Y Performance:
-74.42%
1-Day Range:
$0.63
$1.18
1-Week Range:
$0.63
$1.18
52-Week Range:
$0.63
$5.95
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.8006 | 19.21M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
CITIUS PHARMACEUTICALS Q4 2025 Earnings Preview: Recent $CTXR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Dow Gains Over 100 Points; US Jobless Claims Decline - Benzinga
Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED) - Benzinga
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
UiPath, Ramaco Resources And 3 Stocks To Watch Heading Into Wednesday - Benzinga
Citius Pharmaceuticals Inc. Full Year Loss Decreases - Nasdaq
Citius Pharmaceuticals (CTXR) Reports Wider Annual Loss - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals, Inc. reports fiscal year 2025 financial results and provides business update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update - TradingView — Track All Markets
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Pharmaceuticals (CTXR) Reports Earnings Miss with Increas - GuruFocus
Citius Pharma launches cancer immunotherapy LYMPHIR in the U.S. - Investing.com
CTXR: LYMPHIR's U.S. launch marks a pivotal year, with strong capital raises and ongoing pipeline progress - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
How interest rate cuts could boost Citius Pharmaceuticals Inc. stockShort Setup & Stock Portfolio Risk Management - Улправда
Why Citius Pharmaceuticals Inc. stock remains resilientPortfolio Performance Report & Technical Pattern Based Buy Signals - Улправда
Is Citius Pharmaceuticals Inc. (47N0) stock a safe buy pre earningsExit Point & Daily Oversold Bounce Ideas - Bölüm Sonu Canavarı
Can Citius Pharmaceuticals Inc. stock resist market sell offsWeekly Stock Summary & Proven Capital Preservation Tips - Улправда
Sell Signal: How Citius Pharmaceuticals Inc. stock trades before earnings2025 Biggest Moves & Daily Growth Stock Investment Tips - Улправда
What analyst consensus says on Citius Pharmaceuticals Inc. stockJuly 2025 Recap & Low Risk High Win Rate Picks - DonanımHaber
Layoff Watch: Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsWeekly Profit Summary & Community Consensus Trade Signals - Улправда
Analyst Calls: Will Citius Pharmaceuticals Inc. stock maintain dividend yieldInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
Will Citius Pharmaceuticals Inc. (47N0) stock outperform energy sector in 2025July 2025 Big Picture & Free Weekly Chart Analysis and Trade Guides - DonanımHaber
Will Citius Pharmaceuticals Inc. stock maintain dividend yieldTrade Ideas & Free Real-Time Volume Trigger Notifications - DonanımHaber
Will Citius Pharmaceuticals Inc. stock see insider buyingJuly 2025 Chart Watch & Real-Time Buy Signal Alerts - DonanımHaber
Citius Pharmaceuticals Earnings Notes - Trefis
Is Citius Pharmaceuticals Inc. stock positioned for digital transformationOil Prices & Real-Time Volume Surge Alerts - ulpravda.ru
Why Citius Pharmaceuticals Inc. stock remains a top recommendationJuly 2025 Reactions & Real-Time Chart Breakout Alerts - Улправда
Will Citius Pharmaceuticals Inc. (47N0) stock outperform Dow JonesJuly 2025 PreEarnings & Weekly Return Optimization Plans - Улправда
Can Citius Pharmaceuticals Inc. stock attract ESG capital inflowsWeekly Earnings Recap & Consistent Profit Focused Trading Strategies - Улправда
Quarterly Earnings: How interest rate cuts could boost Citius Pharmaceuticals Inc. stockAnalyst Upgrade & Accurate Entry/Exit Alerts - Улправда
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology (Nasdaq: CTOR) raises $18M at-the-market to fund LYMPHIR - Stock Titan
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Finviz
Aug Selloffs: Is Citius Pharmaceuticals Inc stock positioned for digital transformationPortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Citius Pharmaceuticals Inc. (47N0) stock good for wealth creationJuly 2025 Momentum & Safe Investment Capital Preservation Plans - Newser
How Citius Pharmaceuticals Inc. (47N0) stock reacts to fiscal policiesJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
CTXR: Analyst Jason Kolbert Maintains 'Buy' Rating with $6 Price Target | CTXR Stock News - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times
Citius Oncology Expands LYMPHIR Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - Finviz
How supply shortages influence Citius Pharmaceuticals Inc. (47N0) stockWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
How Citius Pharmaceuticals Inc. (47N0) stock responds to bond market2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):